Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
Theelen WS, Mittempergher L, Willems SM, Bosma AJ, Peters DD, van der Noort V, Japenga EJ, Peeters T, Koole K, Šuštić T, Blaauwgeers JL, van Noesel CJ, Bernards R, van den Heuvel MM. Theelen WS, et al. Among authors: peters dd. J Pathol Clin Res. 2016 Aug 13;2(4):223-233. doi: 10.1002/cjp2.51. eCollection 2016 Oct. J Pathol Clin Res. 2016. PMID: 27785367 Free PMC article.
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R. Majewski IJ, et al. J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209. J Pathol. 2013. PMID: 23661334
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, Velds A, Nieuwland M, van den Heuvel MM, Kerkhoven RM, Wessels LF, Broeks A, van Rhijn BW, Bernards R, van der Heijden MS. Groenendijk FH, et al. Eur Urol. 2016 Mar;69(3):384-8. doi: 10.1016/j.eururo.2015.01.014. Epub 2015 Jan 27. Eur Urol. 2016. PMID: 25636205
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. Sobral-Leite M, et al. Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018. Oncoimmunology. 2018. PMID: 30524905 Free PMC article.
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME, Kuilman T, Schulze K, Zou W, Krijgsman O, Peters DDGC, Cornelissen S, Monkhorst K, Sarma P, Sumiyoshi T, Amler LC, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Kowanetz M. Theelen WSME, et al. Among authors: peters ddgc. PLoS One. 2019 May 24;14(5):e0216864. doi: 10.1371/journal.pone.0216864. eCollection 2019. PLoS One. 2019. PMID: 31125352 Free PMC article.
Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.
Theelen WSME, Krijgsman O, Monkhorst K, Kuilman T, Peters DDGC, Cornelissen S, Ligtenberg MA, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Schulze K. Theelen WSME, et al. Among authors: peters ddgc. J Transl Med. 2020 Jul 3;18(1):271. doi: 10.1186/s12967-020-02436-3. J Transl Med. 2020. PMID: 32620126 Free PMC article.
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K, Thommen DS. Hummelink K, et al. Clin Cancer Res. 2022 Nov 14;28(22):4893-4906. doi: 10.1158/1078-0432.CCR-22-0992. Clin Cancer Res. 2022. PMID: 35852792 Free PMC article.
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA, Kwon MC, Monkhorst K, Song JY, Bhaskaran R, Krijgsman O, Kuilman T, Peters D, Buikhuisen WA, Smit EF, Pritchard C, Cozijnsen M, van der Vliet J, Zevenhoven J, Lambooij JP, Proost N, van Montfort E, Velds A, Huijbers IJ, Berns A. Semenova EA, et al. Cell Rep. 2016 Jul 19;16(3):631-43. doi: 10.1016/j.celrep.2016.06.020. Epub 2016 Jun 30. Cell Rep. 2016. PMID: 27373156 Free PMC article.
65 results